Innogenetics, AdnaGen to develop fetal blood cell screening technology

By Lisa Kerner

Charlotte, N.C., Sept. 19 - Innogenetics NV entered into an exclusive option and evaluation agreement with AdnaGen of Langenhagen, Germany on technology to isolate fetal red blood cells circulating in maternal blood, allowing for prenatal DNA testing.

The need for such testing has increased as the age of women giving birth has increased, along with the associated risk for congenital defects.

Specific details of the agreement were not disclosed.

Innogenetics is an international biopharmaceutical company located in Ghent, Belgium.

© 2015 Prospect News.
All content on this website is protected by copyright law in the U.S. and elsewhere. For the use of the person downloading only.
Redistribution and copying are prohibited by law without written permission in advance from Prospect News.
Redistribution or copying includes e-mailing, printing multiple copies or any other form of reproduction.